Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET

NCT03859921 · tracked via the Priya Life Science China tracker

Sponsor

The University of Hong Kong

Phase

Phase 3

Started

2021-07-01

Last updated

2025-06-12

Condition(s) studied

Subfertility

Investigational drug(s) / intervention(s)

DydrogesteronePlacebo

Dydrogesterone: Progesterone

Placebo: Placebo with appearance similar to Dydrogesterone

Study summary

This randomised double-blinded controlled trial aims to compare the live birth rate in natural FET cycles with and without oral dydrogesterone as luteal phase support. The hypothesis is that the use of oral dydrogesterone will increase the live birth rate of natural cycle FET.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

42 Years

Healthy volunteers

Inclusion Criteria: * Age of women \<43 years at the time of stimulated IVF * Replacing early cleavage embryos or blastocysts after thawing Exclusion Criteria: * Requiring hormonal replacement cycles * Use of donor oocytes or embryos * Undergoing preimplantation genetic testing * Presence of hydrosalpinx not corrected surgically prior to FET * Refusal to join the study

Primary outcome measure(s)

live birth rate — 10 months after recruitment
the number of live birth beyond 22 weeks gestation per transfer cycle

Trial sites (1)

Facility	City	Region	Status
Department of Obstetrics and Gynaecology	Hong Kong	Hong Kong	Recruiting

More The University of Hong Kong trials in China

Emergency PWAS in Respiratory Infectious Disease Recruiting

Pleurodesis in Small-bore Chest Tube Starting soon

GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery Recruiting

Health Chat for Empowerment-based Lifestyle Planning for Cardiometabolic Multimorbidity Recruiting

rTMS for Cerebellar Ataxia in Children Starting soon

Other trials for the same condition

GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03859921 on ClinicalTrials.gov ↗ ← All trials in China